What genetic mutations are commonly found in Stomach Cancer

Genetic Mutations in Stomach Cancer

Stomach cancer (also called gastric cancer) involves several important genetic mutations that doctors test for to guide treatment decisions. Let me explain the key ones and why they matter.

Most Common Mutations in Stomach Cancer

HER2 (ERBB2) Amplification

HER2 is a gene that produces a protein involved in cell growth. When this gene is amplified (too many copies), it can drive cancer growth. HER2 amplification occurs in approximately 15-20% of gastric cancers and is an important finding because:

• It identifies patients who may benefit from targeted therapies like trastuzumab (Herceptin)
• It's one of the most actionable mutations in stomach cancer
• Testing for HER2 status is standard in gastric cancer diagnosis

Mismatch Repair (MMR) Deficiency and Microsatellite Instability (MSI)

These mutations affect the cell's ability to repair DNA errors. When MMR genes (like MLH1, MSH2, MSH6, PMS2) aren't working properly:

• Cells accumulate many mutations (called "hypermutation")
• This can make tumors more responsive to immunotherapy checkpoint inhibitors like nivolumab or pembrolizumab
• According to NCCN Guidelines, universal MMR/MSI testing is recommended for all newly diagnosed gastric cancer patients

KRAS and BRAF Mutations

These are growth-promoting genes:

• KRAS mutations occur in a subset of gastric cancers and affect treatment options
• BRAF mutations (particularly BRAF V600E) are less common but important for treatment planning
• These mutations help doctors decide whether certain targeted therapies will be effective

TP53 Mutations

The TP53 gene normally acts as a "tumor suppressor" (a brake on cell growth). When mutated:

• It's found in a significant portion of gastric cancers
• It's associated with more aggressive disease
• It may influence treatment selection and prognosis

POLE Mutations

DNA polymerase epsilon (POLE) mutations create a "hypermutated" tumor phenotype:

• These tumors have very high mutation burdens
• They often respond well to immunotherapy
• They're associated with better outcomes in some cases

Why Testing Matters

According to NCCN Guidelines and ASCO recommendations, molecular testing of stomach cancer tumors helps doctors:

1. Select targeted therapies - Certain drugs work better for specific mutations
2. Identify immunotherapy candidates - MSI-H/dMMR and high tumor mutation burden tumors often respond to checkpoint inhibitors
3. Assess prognosis - Some mutations indicate more or less aggressive disease
4. Guide family screening - Some mutations (like Lynch syndrome-related MMR genes) can be inherited

Testing Methods

Tumor genetic testing typically uses:

• Next-generation sequencing (NGS) - analyzes multiple genes at once (preferred method)
• Immunohistochemistry (IHC) - checks for protein expression
• Tissue or blood samples - can be performed on tumor tissue or circulating tumor DNA in blood

Key Questions to Ask Your Doctor

If you've been diagnosed with stomach cancer, consider asking:

1. "Has my tumor been tested for HER2, MMR/MSI status, and other molecular markers?"
2. "What mutations were found in my tumor, and what do they mean for my treatment options?"
3. "Am I a candidate for targeted therapy or immunotherapy based on my tumor's genetic profile?"
4. "Should my family members be tested for inherited cancer risk genes?"
5. "Are there clinical trials available for my specific mutation type?"

Important Context

According to NCCN Guidelines, comprehensive molecular profiling via validated and FDA-approved assays is increasingly recommended in the initial evaluation of gastric cancer to facilitate diagnosis and guide treatment decisions. The specific mutations found in your tumor—combined with other factors like stage, location, and your overall health—will help your oncology team determine the best treatment approach for your individual case.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.